Ruilope LM - Search Results

1

Frequency and Prognosis of Treated Hypertensive Patients According to Prior and New Blood Pressure Goals.

Ruilope LM, Ruiz-Hurtado G, Barderas MG, de la Cruz JJ, Lucia A, de la Sierra A, Gorostidi M, Vinyoles E, Segura J, Solís J, Arribas F, García-Puig J, Tamargo J, O'Brien E, Volpe M, Whelton PK, Williams B, Banegas JR. Ruilope LM, et al. Hypertension. 2019 Jul;74(1):130-136. doi: 10.1161/HYPERTENSIONAHA.119.12921. Epub 2019 May 28. Hypertension. 2019. PMID: 31132953

2

Effects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment Study. HOT Study Group.

Zanchetti A, Hansson L, Dahlöf B, Elmfeldt D, Kjeldsen S, Kolloch R, Larochelle P, McInnes GT, Mallion JM, Ruilope L, Wedel H. Zanchetti A, et al. J Hypertens. 2001 Jun;19(6):1149-59. doi: 10.1097/00004872-200106000-00021. J Hypertens. 2001. PMID: 11403365 Clinical Trial.

3

Factors influencing the systolic blood pressure response to drug therapy.

Campo C, Segura J, Ruilope LM. Campo C, et al. Among authors: ruilope lm. J Clin Hypertens (Greenwich). 2002 Jan-Feb;4(1):35-40. doi: 10.1111/j.1524-6175.2002.00487.x. J Clin Hypertens (Greenwich). 2002. PMID: 11821635 Free PMC article. Review.

4

ACE inhibition and cardiovascular mortality and morbidity in essential hypertension: the end of the search or a need for further investigations?

Ruilope LM, Coca A, Volpe M, Waeber B. Ruilope LM, et al. Am J Hypertens. 2002 Apr;15(4 Pt 1):367-71. doi: 10.1016/s0895-7061(02)02258-6. Am J Hypertens. 2002. PMID: 11991225

5

Antihypertensive efficacy and tolerability of lercanidipine in daily clinical practice. The ELYPSE Study. Eficacia de Lercanidipino y su Perfil de Seguridad.

Barrios V, Navarro A, Esteras A, Luque M, Romero J, Tamargo J, Prieto L, Carrasco JL, Herranz I, Navarro-Cid J, Ruilope LM; Investigators of ELYPSE Study (Eficacia de Lercanidipino y su Perfil de Seguridad). Barrios V, et al. Among authors: ruilope lm. Blood Press. 2002;11(2):95-100. doi: 10.1080/08037050211265. Blood Press. 2002. PMID: 12035878 Free article. Clinical Trial.

6

Cyclo-oxygenase-2-specific inhibitors and cardiovascular morbidity.

Ruilope LM, Coca A, Banegas JR, Pablos JL, Luque M. Ruilope LM, et al. Curr Hypertens Rep. 2002 Aug;4(4):261-4. doi: 10.1007/s11906-996-0001-3. Curr Hypertens Rep. 2002. PMID: 12117452 Review. No abstract available.

7

Renal protection by antihypertensive therapy.

Ruilope LM, Segura J. Ruilope LM, et al. Curr Hypertens Rep. 2002 Aug;4(4):324-8. doi: 10.1007/s11906-996-0012-0. Curr Hypertens Rep. 2002. PMID: 12117461 Review.

8

Hypertension guidelines: criteria that might make them more clinically useful.

Alderman MH, Furberg CD, Kostis JB, Laragh JH, Psaty BM, Ruilope LM, Volpe M, Jackson R. Alderman MH, et al. Among authors: ruilope lm. Am J Hypertens. 2002 Oct;15(10 Pt 1):917-23. doi: 10.1016/s0895-7061(02)03001-7. Am J Hypertens. 2002. PMID: 12372681 Review.

9

Proteinuria: an underappreciated risk factor in cardiovascular disease.

Segura J, Campo C, Ruilope LM. Segura J, et al. Among authors: ruilope lm. Curr Cardiol Rep. 2002 Nov;4(6):458-62. doi: 10.1007/s11886-002-0106-5. Curr Cardiol Rep. 2002. PMID: 12379163 Review.

10

Hypertension magnitude and management in the elderly population of Spain.

Banegas JR, Rodríguez-Artalejo F, Ruilope LM, Graciani A, Luque M, de la Cruz-Troca JJ, García-Robles R, Tamargo J, Rey-Calero J. Banegas JR, et al. Among authors: ruilope lm. J Hypertens. 2002 Nov;20(11):2157-64. doi: 10.1097/00004872-200211000-00014. J Hypertens. 2002. PMID: 12409953

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

782 results

Search Page

Filters